Zinc, zinc transporters and diabetes
TL;DR: It is demonstrated that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of ZNT8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance.
read more
Abstract: The role of zinc in islet function has recently achieved new attention as a consequence of the identification of zinc transporter 8 (ZNT8) in islets, and the association of mutations in the gene for this zinc transporter with glucose intolerance and type 2 diabetes. ZNT8 is also an autoantigen associated with the appearance of type 1 diabetes. A number of experimental models have been employed to suggest how ZNT8 and other zinc transporters regulate beta cell insulin processing and possibly secretion. An additional role for the zinc transporters in regulating alpha cell function has been suggested. In this issue of Diabetologia, Wijesekara and colleagues, using a cell-specific Znt8 (also known as Slc30a8) knockout model, demonstrate that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of Znt8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance. Although we are yet to see the therapeutic potential of these new findings, the area represents a field through which manipulation of islet function may eventually be possible.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Zinc as a Gatekeeper of Immune Function
TL;DR: Molecular mechanisms underlying the development of a pro-inflammatory phenotype during zinc deficiency are reported, and links between altered zinc homeostasis and disease development are described, ensuring the benefits of zinc supplementation for a malfunctioning immune system become clear.
610
Antidiabetic Activity of Zinc Oxide and Silver Nanoparticles on Streptozotocin-Induced Diabetic Rats
TL;DR: Zinc oxide and sliver nanoparticles act as potent antidiabetic agents in diabetic rats treated with zinc oxide, silver nanoparticles and insulin.
262
The Concise Guide to PHARMACOLOGY 2015/16: Transporters.
Stephen P.H. Alexander,Eamonn Kelly,Neil V. Marrion,John A. Peters,Helen E. Benson,Elena Faccenda,Adam J. Pawson,Joanna L. Sharman,Christopher Southan,Jamie A. Davies +9 more
TL;DR: The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands ( www.guidetopharmacology.org ), which provides more detailed views of target and ligand properties.
Current understanding of ZIP and ZnT zinc transporters in human health and diseases
TL;DR: The present review summarizes the current understanding of ZIP and ZnT transporter functions from the standpoint of human health and diseases and indicates that comprehensive understanding is far from complete.
240
Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats
TL;DR: Oral administration of zinc oxide nanoparticles resulted in significant antidiabetic effects--that is, improved glucose tolerance, higher serum insulin, reduced blood glucose, reduced nonesterified fatty acids, and reduced triglycerides.
219
References
A genome-wide association study identifies novel risk loci for type 2 diabetes
Robert Sladek,Ghislain Rocheleau,Johan Rung,Christian Dina,Lishuang Shen,David Serre,Philippe Boutin,Daniel Vincent,Alexandre Belisle,Samy Hadjadj,Beverley Balkau,Barbara Heude,Guillaume Charpentier,Thomas J. Hudson,Thomas J. Hudson,Alexandre Montpetit,Alexey V. Pshezhetsky,Marc Prentki,Barry I. Posner,David J. Balding,David Meyre,Constantin Polychronakos,Philippe Froguel,Philippe Froguel +23 more
TL;DR: Four loci containing variants that confer type 2 diabetes risk are identified and constitute proof of principle for the genome-wide approach to the elucidation of complex genetic traits.
3.2K
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes
Janet M. Wenzlau,Kirstine Juhl,Kirstine Juhl,Liping Yu,Ong Moua,Suparna A. Sarkar,Peter A. Gottlieb,Marian Rewers,George S. Eisenbarth,Jan Jensen,Howard W. Davidson,John C. Hutton +11 more
TL;DR: The combined measurement of ZnT8A, GADA, IA2A, and IAA raised autoimmunity detection rates to 98% at disease onset, a level that approaches that needed to detect prediabetes in a general pediatric population.
1K
Identification and Cloning of a β-Cell–Specific Zinc Transporter, ZnT-8, Localized Into Insulin Secretory Granules
TL;DR: It is demonstrated by RT-PCR on cDNA libraries and human tissue extracts that the ZnT-8 gene is solely transcribed in the pancreas, mainly in the islets of Langerhans, and this gene is a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells.
517
Zinc and diabetes--clinical links and molecular mechanisms.
TL;DR: The influence of zinc on the diabetic state including the molecular mechanisms, the role of the zinc transporter 8 and MT for diabetes development and the resulting diagnostic and therapeutic options are reviewed.
448
Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants
Tamara J. Nicolson,Elisa A. Bellomo,Nadeeja Wijesekara,Merewyn K. Loder,Jocelyn M. Baldwin,Armen V. Gyulkhandanyan,Vasilij Koshkin,Andrei I. Tarasov,Raffaella Carzaniga,Katrin Kronenberger,Tarvinder K. Taneja,Gabriela da Silva Xavier,Sarah Libert,Philippe Froguel,Philippe Froguel,Raphael Scharfmann,Volodymir Stetsyuk,Philippe Ravassard,Helen E. Parker,Fiona M. Gribble,Frank Reimann,Robert Sladek,Stephen J. Hughes,Paul Johnson,Myriam Masseboeuf,Rémy Burcelin,Stephen A. Baldwin,Ming Liu,Roberto Lara-Lemus,Peter Arvan,Frans Schuit,Michael B. Wheeler,Fabrice Chimienti,Guy A. Rutter +33 more
TL;DR: ZnT8 is required for normal insulin crystallization and insulin release in vivo but not, remarkably, in vitro, and defects in the former processes in carriers of the R allele may increase type 2 diabetes risks.
394
Related Papers (5)
Tamara J. Nicolson,Elisa A. Bellomo,Nadeeja Wijesekara,Merewyn K. Loder,Jocelyn M. Baldwin,Armen V. Gyulkhandanyan,Vasilij Koshkin,Andrei I. Tarasov,Raffaella Carzaniga,Katrin Kronenberger,Tarvinder K. Taneja,Gabriela da Silva Xavier,Sarah Libert,Philippe Froguel,Philippe Froguel,Raphael Scharfmann,Volodymir Stetsyuk,Philippe Ravassard,Helen E. Parker,Fiona M. Gribble,Frank Reimann,Robert Sladek,Stephen J. Hughes,Paul Johnson,Myriam Masseboeuf,Rémy Burcelin,Stephen A. Baldwin,Ming Liu,Roberto Lara-Lemus,Peter Arvan,Frans Schuit,Michael B. Wheeler,Fabrice Chimienti,Guy A. Rutter +33 more